Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

NCT ID: NCT02355535

Last Updated: 2020-09-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-02-28
• Study Completion Date: 2020-05-18

Brief Summary

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. As of March 1, 2019, only patients with neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Conditions

Solid Tumor; Pancreatic Neuroendocrine Tumor; Neuroendocrine Tumors

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Open label

Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.

Group Type: EXPERIMENTAL

PAC-1

Intervention Type: DRUG

PAC-1 is taken orally on days 1-21 of a 28-day cycle.

Interventions

PAC-1

PAC-1 is taken orally on days 1-21 of a 28-day cycle.

Intervention Type: DRUG

Other Intervention Names

Procaspase Activating Compound-1

Eligibility Criteria

Inclusion Criteria

1. Male or female ≥ 18 years of age

2. Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy

3. Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria

4. Has an ECOG PS of 0, 1, or 2

5. Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or < 3 x ULN for subjects with known hepatic metastases

6. Has serum creatinine < 1.5 × ULN

7. Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L

8. Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration

9. Must be willing and able to comply with study

10. Has read, understood, and signed the ICF

11. Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP

12. Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative

13. Prior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy

14. Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated

Exclusion Criteria

1. Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)

2. Gliomas are excluded, as well as any history of brain metastases, seizures or underlying brain injury

3. May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.

4. Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment

5. Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina

6. Has uncontrolled HIV or hepatitis B or C

7. Has any clinically significant infection

8. Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF

9. Radiation therapy to more than 25% of the bone marrow

10. Prior allogeneic bone marrow or organ transplantation

11. > Grade 1 peripheral neuropathy within 14 days before enrollment.

12. Patient has received other investigational drugs with 14 days before enrollment

13. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation

14. Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)

15. Presence of any non-healing wound, fracture, or ulcer

16. Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance

17. Has any mental or medical condition that prevents the patient from giving informed consent

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Illinois at Chicago

OTHER

Sponsor Role: collaborator

Vanquish Oncology, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Oana Danciu, MD

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Oana C Danciu, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of Illinois at Chicago

Locations

University of Illinois at Chicago

Chicago, Illinois, United States

Johns Hopkins Kimmel Cancer Center

Baltimore, Maryland, United States

Regions Hospital

Saint Paul, Minnesota, United States

Countries

United States

References

Danciu OC, Holdhoff M, Peterson RA, Fischer JH, Liu LC, Wang H, Venepalli NK, Chowdhery R, Nicholas MK, Russell MJ, Fan TM, Hergenrother PJ, Tarasow TM, Dudek AZ. Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. Br J Cancer. 2023 Mar;128(5):783-792. doi: 10.1038/s41416-022-02089-7. Epub 2022 Dec 5.

Reference Type: DERIVED

PMID: 36470974 (View on PubMed)

Other Identifiers

2015-0057

Identifier Type: -

Identifier Source: org_study_id